chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 52.0
Sex: U
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 24.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State  for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 92.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 22.0
Sex: M
Vaccine: COVID19
Symptoms: Dizziness, Loss of consciousness, Urinary incontinence
Clinical narrative: PATIENT FELT DIZZY AND SAID HE LOST CONSCIOUS FOR FEW MINUTES AND THEN WOKE UP . WHEN I SAW THE PATIENT HE WAS AWAKE BUT FELT LIGHT HEADED. I LAID HIM ON THE FLOOR AND ELEVEATED HIS LEGS ON A CHAIR. I CHECKED HIS BLOOD PRESSURE 4 TIMES WITH 2 DIFFERENT MONITORS AND IT WAS BETWEEN  130/90 . I GOT HIM WATER AND HE DRANK HALF OF A BOTTLE ,. HE STAYED ON THE FLOOR FOR 10 MINUTES AND THEN WAS ABLE TO GET UP AND WENT HOM WITH HIS MOTHER. I CALLED AND CHECKED ON HIM AFTE 1 AND THEN 3 HOURS AND HE SAID HE WAS FEELING NORMAL . PATIENT ALSO SAID HE LOST CONTROL OF HIS BLADDER WHEN HE WAS SITTING ON THE CHAIR.
Age: 4.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 27.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 74.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was  refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State  for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 39.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 80.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was Cardinal refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 67.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by the Regulatory Authority for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 47.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 51.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 58.0
Sex: F
Vaccine: UNK
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 94.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 48.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 37.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 35.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 29.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 42.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 53.0
Sex: F
Vaccine: DTAPHEPBIP
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 26.0
Sex: U
Vaccine: DTAPIPV
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 37.0
Sex: F
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 43.0
Sex: M
Vaccine: COVID19
Symptoms: No adverse event, Product storage error
Clinical narrative: On the clinic day, the vaccine was transported out from the pharmacy to the facility without a digital data logger. The packing used for transport was a refrigerated packaging tote to maintain a temperature of 36 F - 46 F.  However, that is not approved by State for COVID-19 vaccine transportation. The total time (from when vaccine left the pharmacy to the clinic completion) was less than 6 hours. There were no adverse events.
Age: 10.0
Sex: M
Vaccine: COVID19
Symptoms: Fatigue, Product preparation issue
Clinical narrative: The pharmacist contacted me about thirty minutes after the injection that they had accidentally injected my son with an undiluted vial of vaccine. She stated that the vial was an older vial that required dilution and they had confused it with a newer vial that didn?t require dilution. She could not tell me how much vaccine my son had actually received. She told me to watch him closely for the next few days and to give Tylenol or ibuprofen as needed for increased adverse reactions. No symptoms so far aside from increased fatigue, at 9:30 pm on the day the vaccine was given.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Burning sensation, Erythema, Foot deformity, Hypoaesthesia
Clinical narrative: Two day after booster, sudden onset of paresthesia (pins and needles, tingling) in both feet and legs, both hands and arms. Joint pain in feet. Within 2 weeks the paresthesia had increased two fold as had the joint pain preventing sleep. Also within a month soles of feet became bright red and burned, skin on left bunion joint turned purple, decreased sensation/numbness in heels, joint pain in legs and back, joint swelling in feet and hands.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Joint swelling, Laboratory test, Paraesthesia, Sensory loss, Skin discolouration
Clinical narrative: Two day after booster, sudden onset of paresthesia (pins and needles, tingling) in both feet and legs, both hands and arms. Joint pain in feet. Within 2 weeks the paresthesia had increased two fold as had the joint pain preventing sleep. Also within a month soles of feet became bright red and burned, skin on left bunion joint turned purple, decreased sensation/numbness in heels, joint pain in legs and back, joint swelling in feet and hands.
Age: 66.0
Sex: F
Vaccine: COVID19
Symptoms: Sleep disorder, Small fibre neuropathy
Clinical narrative: Two day after booster, sudden onset of paresthesia (pins and needles, tingling) in both feet and legs, both hands and arms. Joint pain in feet. Within 2 weeks the paresthesia had increased two fold as had the joint pain preventing sleep. Also within a month soles of feet became bright red and burned, skin on left bunion joint turned purple, decreased sensation/numbness in heels, joint pain in legs and back, joint swelling in feet and hands.
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: COVID-19, Chills, Cough, Oropharyngeal pain, Pain
Clinical narrative: Positive Covid: started with sore throat and fever, progressed to body aches and chills by evening of first day, then tested positive on at-home test, cough developed on second day and fever and body aches continued through third day, by day 7 was back to normal
Age: 39.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Pyrexia, SARS-CoV-2 test positive
Clinical narrative: Positive Covid: started with sore throat and fever, progressed to body aches and chills by evening of first day, then tested positive on at-home test, cough developed on second day and fever and body aches continued through third day, by day 7 was back to normal
Age: 12.0
Sex: F
Vaccine: TDAP
Symptoms: Seizure
Clinical narrative: Patient received Tdap (Adacel) vaccine in consultation in the pharmacy with mother in the room. Patient began what appeared to be convulsing with a duration of less than one minute. Patient did not exhibit any additional symptoms after initial presentation. Emergency services were contacted per her mother's request, and patient and mother left the store with them.
Age: 57.0
Sex: F
Vaccine: COVID19
Symptoms: Asthenia, Joint range of motion decreased, Limb discomfort, Muscular weakness, Pain in extremity
Clinical narrative: Since my third Pfizer shot, I have issues with my left arm. I have a limited range of motion, some pain and weakness. When I got my fourth shot, I told this nurse about this experience and she asked me to report it through this site.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Chest pain, Dyspnoea, Fatigue
Clinical narrative: Intense chest pain for three days, 14 days of moderate chest pain, fatigue and breathlessness. Symptoms gradually improved.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Blood testosterone normal, Chest discomfort, Chest pain, Chills, Dyspnoea
Clinical narrative: Intense chest pain for three days, 14 days of moderate chest pain, fatigue and breathlessness. Symptoms gradually improved.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Electrocardiogram abnormal, Exercise tolerance decreased, Fatigue, Fear, Full blood count normal
Clinical narrative: Intense chest pain for three days, 14 days of moderate chest pain, fatigue and breathlessness. Symptoms gradually improved.
Age: 29.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Oestradiol normal, Pyrexia, Sinus arrhythmia
Clinical narrative: Intense chest pain for three days, 14 days of moderate chest pain, fatigue and breathlessness. Symptoms gradually improved.
Age: 69.0
Sex: F
Vaccine: UNK
Symptoms: COVID-19, Ear pain, Exposure to SARS-CoV-2, Oropharyngeal pain, SARS-CoV-2 test positive
Clinical narrative: None stated.
Age: 69.0
Sex: F
Vaccine: UNK
Symptoms: Sinus pain
Clinical narrative: None stated.
Age: 60.0
Sex: F
Vaccine: FLUC4
Symptoms: Echocardiogram, Electrocardiogram ambulatory, Electrocardiogram ambulatory abnormal, Ventricular tachycardia
Clinical narrative: Ventricular tachcardia
Age: 32.0
Sex: M
Vaccine: COVID19
Symptoms: Pain, Pruritus
Clinical narrative: Pain and itching all over body. Especially in the feet, arms, legs and hands. Same thing happened to me after my second dosage. Except back in October 2021 I ended up in the hospital five days later. Now I am experiencing that same pain, but unfortunately at this point in the middle of a job transition there is a lapse in my insurance.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Cardiac discomfort, Cardiac flutter, Cardiac stress test normal, Chest discomfort, Dyspnoea
Clinical narrative: Symptoms were not critical but I began experiencing sensations and pressure in my chest area. It happens most often on the left side of my chest but I have felt it in the middle as well as on the right side of my chest.  I had a lot of instances were I felt like I was out of oxygen. I would breathe deeply and it would pass. There were times when I was sitting and working at my computer and it would feel as if my heart was just out of energy - I'd have to breathe deeply and it would pass in seconds. Because I didn't have anything to compare the first Booster shot to, I went through a plethora of test on my heart to ensure I was alright. Agency did not find anything but they did say that I had a leaky heart valve. Dr. reported that it is somewhat common and it is not a major problem currently. These sensations went on for a while and then tapered off. Sometimes it felt like pressure, other times like a cat walking across my chest, or like little fluttering sensations. It never really hurt bit I knew something was going on.   On May 3, 2022, I took my second vaccine. The sensations started immediately, approximately 30 minutes after leaving Agency. I felt pressure, as if I didn't have the normal amount of oxygen. I'd have to breathe deeply and that would help to clear up the feeling. These sensations do not last for long periods of time but I might feel them, as of today, about two to three times a day. When they first started, I could feel them maybe 5 or 6 times a day. It does seem like the sensation episodes are getting further and further apart.
Age: 62.0
Sex: F
Vaccine: COVID19
Symptoms: Echocardiogram abnormal, Heart valve incompetence, Mitral valve disease
Clinical narrative: Symptoms were not critical but I began experiencing sensations and pressure in my chest area. It happens most often on the left side of my chest but I have felt it in the middle as well as on the right side of my chest.  I had a lot of instances were I felt like I was out of oxygen. I would breathe deeply and it would pass. There were times when I was sitting and working at my computer and it would feel as if my heart was just out of energy - I'd have to breathe deeply and it would pass in seconds. Because I didn't have anything to compare the first Booster shot to, I went through a plethora of test on my heart to ensure I was alright. Agency did not find anything but they did say that I had a leaky heart valve. Dr. reported that it is somewhat common and it is not a major problem currently. These sensations went on for a while and then tapered off. Sometimes it felt like pressure, other times like a cat walking across my chest, or like little fluttering sensations. It never really hurt bit I knew something was going on.   On May 3, 2022, I took my second vaccine. The sensations started immediately, approximately 30 minutes after leaving Agency. I felt pressure, as if I didn't have the normal amount of oxygen. I'd have to breathe deeply and that would help to clear up the feeling. These sensations do not last for long periods of time but I might feel them, as of today, about two to three times a day. When they first started, I could feel them maybe 5 or 6 times a day. It does seem like the sensation episodes are getting further and further apart.
Age: 37.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: Echocardiogram normal, Electrocardiogram normal, Magnetic resonance imaging normal, Seizure
Clinical narrative: first seizure experienced 6/19/21, second 8/04/21, third 9/14/21, fourth 1/29/22, fifth 3/25/22.  Never had any type of seizure disorder ever, no history of seizure disorder in family
Sex: U
Vaccine: HEPA
Symptoms: Expired product administered, Vaccination error
Clinical narrative: Misread expiration date on vaccine given. Physician was immediately notified or error.
Sex: U
Vaccine: HPV9
Symptoms: Unevaluable event
Clinical narrative: Patient presented to clinic for appointment. Patient requested HPV vaccine. Provider did not see previous vaccination history in the EMR. Nursing did not check for prior vaccination. HPV vaccination ordered per provider and administered per nursing staff.
Sex: U
Vaccine: COVID19
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Pfizer 12y &up vaccine use for COVID-19 under Emergency Use Authorization (EUA): Pt is in for nurse only visit for 2nd Pfizer COVID vaccine. 1st vaccine administered on 4/11/22. LPN staff nurse administered 2nd dose and this was 4 days too early.
Sex: U
Vaccine: MNQ, UNK
Symptoms: Expired product administered
Clinical narrative: Patient was given two vaccines. the menactra vaccine was expired. Expired in April 2022. Nurse giving vaccines was alone in pod without another nurse for second check. the vaccine was confirmed by the provider but dates were not checked. nurse contacted me by phone to explain what happened in the chart. verbal education was given over the phone about the second check reminders and to input the vaccine information in prior to administering. nurse was also provided face to face education again the next morning.
Sex: U
Vaccine: HEPA
Symptoms: Expired product administered
Clinical narrative: Misread expiration date on vaccine. When discovered immediately reported to physician.
Age: 65.0
Sex: M
Vaccine: VARZOS
Symptoms: Anaphylactic reaction, Syncope
Clinical narrative: 1. Anaphylaxis, 2. Syncope
Sex: U
Vaccine: PNC13
Symptoms: Wrong product administered
Clinical narrative: Wrong vaccine given to patient. Provider verbally told nurse to administer pneumovax 23, nurse misunderstood and administered prevnar 13. Nurse did attempt a second check on the vaccine she was giving with another RN however the order was not verified prior to administering by either nurse. Nurse advised leadership, provider, and contacted the patient to let her know what happened. Education was given to both nurses on the proper second check procedure. Education also given to provider to ensure she is given clear verbal orders and to ensure that the order is signed prior to administering. Add: Medwatch submitted 4/12/22
Sex: U
Vaccine: MMR
Symptoms: Swelling face
Clinical narrative: Reported to Employee Health with swelling of her right lower jaw area which she is attributing to her MMR shot on 3/29/22. Her start date with company is 4/4/22.
Sex: U
Vaccine: HEPA
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Patient was given a second vaccine dose of Hepatitis A approximately 44 days after first dose was given. The recommended interval between 1st and 2nd doses is 6 months. This was noted until 4/20/22 when patient called the Employee Health office to schedule a visit to receive the 2nd Hepatitis A vaccine.
Sex: U
Vaccine: MMR
Symptoms: Inappropriate schedule of product administration
Clinical narrative: Employee made appointment to have MMR given on 4/22/2022. MMR was given. I went to remove from recall list and noticed that the email I had sent her stated she could have on or before 4/29/2022. MMR was received to early. Employee was contacted and scenario was reviewed and she was notified of having to receive her MMR in May for best immunity. Employee apologized for scheduling prior to date listed on her email. No further questions by employee.
Sex: U
Vaccine: COVID19
Symptoms: Immunodeficiency, Wrong product administered
Clinical narrative: Pt is immunocompromised and was given Jansen Covid for 2nd dose 10/29/2021 and Booster dose 04/13/2022. Technically patient (immunocompromised) should have been given mRNA vaccine for each of these doses (Pfizer or Moderna). However, CDC guidelines and literature suggest that if patient really wants to have J&J vaccine due to preference/insistence and no previous reaction then they cannot be forced into another vaccine.
Age: 52.0
Sex: F
Vaccine: VARZOS
Symptoms: Chills, Dizziness, Pain in extremity
Clinical narrative: CHILLS / DIZZINESS / ARM PAIN
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Blepharospasm, Blood test normal, Cardiac monitoring abnormal, Condition aggravated, Heart rate irregular
Clinical narrative: Shortly after receiving the second does of the COVID Vaccine my right eye twitched a lot for about a month.  After receiving the booster shot I started having palpitations and irregular heart beats continually though out the day & night. I contacted my GP because in the past palpitations would be a sign that my thyroid medication was off. She did blood work and my levels where normal but the palpitations/irregular heart beats did not stop. She put me on a heart monitor for thirty days.  I still have irregular heart beats & palpitations.
Age: 51.0
Sex: F
Vaccine: COVID19, COVID19, COVID19
Symptoms: Palpitations, Supraventricular extrasystoles, Thyroid function test normal, Ventricular extrasystoles
Clinical narrative: Shortly after receiving the second does of the COVID Vaccine my right eye twitched a lot for about a month.  After receiving the booster shot I started having palpitations and irregular heart beats continually though out the day & night. I contacted my GP because in the past palpitations would be a sign that my thyroid medication was off. She did blood work and my levels where normal but the palpitations/irregular heart beats did not stop. She put me on a heart monitor for thirty days.  I still have irregular heart beats & palpitations.
Age: 46.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Tested positive for COVID-19 (PCR test); Tested positive for COVID-19 (PCR test); This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (BNT162B2), on 18Mar2021 as dose 1, single (Batch/Lot number: unknown), in left arm, on 08Apr2021 as dose 2, single (Batch/Lot number: unknown), in left arm and on 15Nov2021 as dose 3 (booster), single (Batch/Lot number: unknown) at the age of 46 years, in left arm, all intramuscular for covid-19 immunization. Facility where the most recent COVID-19 vaccine was administered was reported as Other, Pfizer. The patient's relevant medical history was not reported. Concomitant medication(s) included: ESCITALOPRAM; ATORVASTATIN, also reported as other medications in two weeks. The patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient had not been diagnosed with COVID-19 prior to vaccination and has been tested since the vaccination. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 18May2022, outcome "recovering" and all described as "Tested positive for COVID-19 (PCR test)". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (16May2022) Positive, notes: Nasal Swab; (18May2022) Positive. Therapeutic measures were not taken as a result of vaccination failure, covid-19.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: COVID-19, Chills, Headache, Nasal congestion, Nasal discomfort
Clinical narrative: Nasal Swab: positive /I subsequently tested positive on a Rapid home test.; Nasal Swab: positive /I subsequently tested positive on a Rapid home test.; rawness in nasal passages and mouth; rawness in nasal passages and mouth; headache; chills; congestion; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (COMIRNATY), on 03Mar2021 as dose 1, single (Lot number: EL3247), in left arm, on 24Mar2021 as dose 2, single (Lot number: EL3247), in left arm and on 19Nov2021 at 15:00 as dose 3 (booster), single (Lot number: FF2593) at the age of 47 years, in left arm, all intramuscular for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: NASAL CONGESTION (non-serious) with onset 16May2021, outcome "recovering", described as "congestion"; CHILLS (non-serious) with onset 16May2022, outcome "recovering"; HEADACHE (non-serious) with onset 16May2022, outcome "recovering"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 16May2022 at 10:00, outcome "recovering" and all described as "Nasal Swab: positive /I subsequently tested positive on a Rapid home test."; STOMATITIS (non-serious), NASAL DISCOMFORT (non-serious) all with onset 16May2022 at 10:00, outcome "recovering" and all described as "rawness in nasal passages and mouth". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (16May2022) Positive, notes: I subsequently tested positive on a Rapid home test. Covid test type post vaccination=Nasal Swab. Therapeutic measures were taken as a result of vaccination failure, covid-19, stomatitis, nasal discomfort, headache, chills, nasal congestion. Clinical course of the events: Facility type vaccine: Hospital. Other vaccine in four weeks: No. Other medications in two weeks: No. Adverse event: Patient( the reporter) experience COVID19 symptoms. Specifically, rawness in nasal passages and mouth. I subsequently tested positive on a Rapid home test. Later that day, experienced chills, congestion, and headache. Symptoms are mild, but continuing. Adverse event treatment: Tylenol. covid prior vaccination: No. covid tested post vaccination: Yes.  No follow-up attempts are possible. No further information is expected.
Age: 47.0
Sex: M
Vaccine: COVID19
Symptoms: SARS-CoV-2 test, Stomatitis, Vaccination failure
Clinical narrative: Nasal Swab: positive /I subsequently tested positive on a Rapid home test.; Nasal Swab: positive /I subsequently tested positive on a Rapid home test.; rawness in nasal passages and mouth; rawness in nasal passages and mouth; headache; chills; congestion; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 47-year-old male patient received BNT162b2 (COMIRNATY), on 03Mar2021 as dose 1, single (Lot number: EL3247), in left arm, on 24Mar2021 as dose 2, single (Lot number: EL3247), in left arm and on 19Nov2021 at 15:00 as dose 3 (booster), single (Lot number: FF2593) at the age of 47 years, in left arm, all intramuscular for covid-19 immunisation. The patient's relevant medical history was not reported. There were no concomitant medications. The following information was reported: NASAL CONGESTION (non-serious) with onset 16May2021, outcome "recovering", described as "congestion"; CHILLS (non-serious) with onset 16May2022, outcome "recovering"; HEADACHE (non-serious) with onset 16May2022, outcome "recovering"; VACCINATION FAILURE (medically significant), COVID-19 (medically significant) all with onset 16May2022 at 10:00, outcome "recovering" and all described as "Nasal Swab: positive /I subsequently tested positive on a Rapid home test."; STOMATITIS (non-serious), NASAL DISCOMFORT (non-serious) all with onset 16May2022 at 10:00, outcome "recovering" and all described as "rawness in nasal passages and mouth". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (16May2022) Positive, notes: I subsequently tested positive on a Rapid home test. Covid test type post vaccination=Nasal Swab. Therapeutic measures were taken as a result of vaccination failure, covid-19, stomatitis, nasal discomfort, headache, chills, nasal congestion. Clinical course of the events: Facility type vaccine: Hospital. Other vaccine in four weeks: No. Other medications in two weeks: No. Adverse event: Patient( the reporter) experience COVID19 symptoms. Specifically, rawness in nasal passages and mouth. I subsequently tested positive on a Rapid home test. Later that day, experienced chills, congestion, and headache. Symptoms are mild, but continuing. Adverse event treatment: Tylenol. covid prior vaccination: No. covid tested post vaccination: Yes.  No follow-up attempts are possible. No further information is expected.
Age: 35.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, Drug ineffective, Malaise, SARS-CoV-1 test
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 36-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Mar2021 as dose 1 , single (Lot number: EM0204), in left arm and on 06Apr2021 as dose 2, single (Lot number: EW0151) at the age of 35 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 06Nov2021 as dose 3 (booster), single (Lot number: 051F21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Keflex, reaction(s): "known allergies: Keflex". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (May2022) Negative, notes: Roughly 5-6 days after finishing the anti-vitals, and after testing negative, I started feeling sick and tested positive again; (May2022) Positive, notes: Roughly 5-6 days after finishing the anti-vitals, and after testing negative, I started feeling sick and tested positive again. Therapeutic measures were taken as a result of vaccination failure, covid-19.It was reported that Other medications in two weeks as Birth control brand name Camila.
Age: 35.0
Sex: F
Vaccine: COVID19, COVID19
Symptoms: COVID-19, SARS-CoV-2 test, Vaccination failure
Clinical narrative: Treatment of COVID-19; Treatment of COVID-19; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 36-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), on 16Mar2021 as dose 1 , single (Lot number: EM0204), in left arm and on 06Apr2021 as dose 2, single (Lot number: EW0151) at the age of 35 years, in left arm for covid-19 immunisation; coviD-19 vaccine mrna (mrna 1273) (MODERNA COVID-19 VACCINE), on 06Nov2021 as dose 3 (booster), single (Lot number: 051F21A), in left arm for covid-19 immunisation. The patient's relevant medical history included: "High blood pressure" (unspecified if ongoing). The patient took concomitant medications. Past drug history included: Keflex, reaction(s): "known allergies: Keflex". The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "not recovered" and all described as "Treatment of COVID-19". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive; (May2022) Negative, notes: Roughly 5-6 days after finishing the anti-vitals, and after testing negative, I started feeling sick and tested positive again; (May2022) Positive, notes: Roughly 5-6 days after finishing the anti-vitals, and after testing negative, I started feeling sick and tested positive again. Therapeutic measures were taken as a result of vaccination failure, covid-19.It was reported that Other medications in two weeks as Birth control brand name Camila.
Age: 86.0
Sex: M
Vaccine: COVID19
Symptoms: Injection site discolouration
Clinical narrative: Black and blue mark at vaccination site approx 2 x 2 inches in size. Discovered at 9PM 5/21/2022
Age: 58.0
Sex: F
Vaccine: VARZOS
Symptoms: Varicella
Clinical narrative: Chicken Pox
Age: 25.0
Sex: F
Vaccine: COVID19
Symptoms: Oropharyngeal pain, Rash macular, Throat tightness
Clinical narrative: Sore throat/tightness in throat, splotchy redness in face
Sex: U
Vaccine: MMR
Symptoms: Expired product administered, No adverse event
Clinical narrative: Caller refused additional AE; An expired dose of MMR II was administered to a patient.; This spontaneous report was received from a registered nurse referring to a patient of unspecified age and gender whose medical history, concurrent conditions, previous adverse drug reaction, or family adverse drug reactions were not provided.  On 19-APR-2022, the patient was vaccinated with an expired dose of measles, mumps, and rubella (wistar ra 27-3) virus vaccine, live recombinant human albumin (rha) (M-M-R II) subcutaneous injection, for prophylaxis (dose, route of administration, anatomical location, and vaccine scheme were not provided; lot number T012806 was determined to be a valid lot number, expiration date reported and established as 14-APR-2022).  There were refused additional adverse events (AE) (no adverse event). It was reported that no temperature excursion on the vaccine was made.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: Patient did not have any symptoms or adverse effects of receiving vaccine; administration of vaccine following temperature excursion/ Temperature: -13.0C; This spontaneous report was received from a medical assistant and refers to a patient of unknown age and gender.  The patient's medical history, concurrent conditions, and previous drug reactions or allergies were not reported. Concomitant medications included sterile diluent (MERCK STERILE DILUENT).  On 14-APR-2022, the patient was administered varicella virus vaccine live (oka/merck) (VARIVAX) 0.5 milliliters (ml) once for prophylaxis following a temperature excursion of -13.0 Celsius (C) for 1 hour (product storage error) (valid lot number U024221, with expiration date 04-AUG-2023; dose number, vaccination scheme, route and anatomical location of vaccination were not reported). There was no previous temperature excursion.   The patient did not have any symptoms or adverse effects from receiving the vaccine (no adverse event).
Sex: U
Vaccine: MMRV
Symptoms: No adverse event, Product storage error
Clinical narrative: Patient did not have any symptoms or adverse effects of receiving vaccine; Administration of vaccine following temperature excursion; This spontaneous report was received from a medical assistant referring to a patient of unknown age and gender whose medical history and concurrent conditions were not reported. The patient's concomitant medication included sterile diluent (MERCK STERILE DILUENT).  On 19-APR-2022, the patient was vaccinated with measles, mumps, rubella, and varicella (oka-merck) virus vaccine live (PROQUAD) subcutaneous injection, at a dose of 0.5 milliliters (ml), once (strength, route of administration, anatomical location, and vaccine scheme were not reported; lot number U028179 was determined to be a valid lot number, expiration date reported and established as 08-MAR-2023) for prophylaxis.  The administered dose of the suspect vaccine experienced a temperature excursion of -13 degrees Celsius (°C) for 1 hour (product storage error). There was no previous temperature excursion. No additional adverse events (AE) were reported (no adverse event).
Age: 2.0
Sex: F
Vaccine: HEPA
Symptoms: Expired product administered, No adverse event
Clinical narrative: No additional AE reported.; Nurse reported that VAQTA with an expiration date of 5/2/2022 was administered to a patient today (5/10/2022). She was requesting guidance on this. No additional AE reported. No PQC reported. No further information was provided.; This spontaneous report has been received from a nurse and refers to a 2-year-old female patient.  The patient's medical history, current conditions, concomitant therapies, and previous drugs reactions or allergies were not reported.  On 10-MAY-2022, the patient was vaccinated with an expired hepatitis a vaccine, inactivated (VAQTA) intramuscular injection, at a dose of 0.5 milliliter, lot number U003464, expiration date: 02-MAY-2022 for prophylaxis (vaccination scheme, route of administration and anatomical site of application were not reported) (expired product administered). No adverse event was reported.
Sex: U
Vaccine: VARCEL
Symptoms: No adverse event, Product storage error
Clinical narrative: No additional AE reported; Vaccine coordinator is reporting the administration of improperly stored vaccines to unknown patients after the temperature excursion on 20-JAN-2022; This spontaneous report has been received from a vaccine coordinator concerning a patient of unreported age and gender. The patient's pertinent medical history, concurrent conditions, previous drug reactions, allergies, and concomitant medications were not provided.  On 20-JAN-2022, the patient was administered vaccine varicella virus vaccine live (oka/merck) (VARIVAX) (valid lot number U020244 [expiration date 28-JUN-2023]) for prophylaxis, after a temperature excursion of -14 degrees Celsius (C) for 7 hours (h) (product storage error) (dose number, vaccination scheme frequency, route, and anatomical location of vaccination were not provided). No previous temperature excursion was reported.   No additional adverse events (AE) were reported.  This is one of several reports received from the same reporter.; Sender's Comments:  US-009507513-2205USA005023:02167763 US-009507513-2205USA004990:02167746 US-009507513-2205USA005084:02167789 US-009507513-2205USA005071:02167774 US-009507513-2205USA005002:02167802 US-009507513-2205USA004997:02167739 US-009507513-2205USA005229:02167797 US-009507513-2205USA005130:02167643 US-009507513-2205USA005126:02167756